Utah-based AI biotech company Recursion Pharmaceuticals has entered a multi-year agreement with precision medicine genomic solutions provider Helix, to accelerate drug discovery using population health data and AI.
According to the agreement, Recursion will gain the rights to use de-identified clinico-genomic data provided by Helix, collected from consenting research participants across the US. It plans to use the obtained data to train its AI models to create biomarkers and form strategies for patient stratification across multiple diseases
By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.